$ACET
Adicet Bio, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020022817 Filed on May 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q4
Revenue $9.470M $0.00 $0.00
YoY Change 56.01%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.400M $2.540M $3.330M
YoY Change 436.23% -10.56% 65.67%
% of Gross Profit
Research & Development $8.676M $7.033M $26.11M
YoY Change -47.59% -20.55% 500.23%
% of Gross Profit
Depreciation & Amortization $40.00K $30.00K $40.00K
YoY Change 33.33% 0.0% 100.0%
% of Gross Profit
Operating Expenses $16.10M $9.557M $29.44M
YoY Change -16.04% -18.25% 362.89%
Operating Profit -$8.630M -$29.44M
YoY Change -54.98% 362.83%
Interest Expense $34.00K $2.820M
YoY Change
% of Operating Profit
Other Income/Expense, Net -$20.00K $70.00K -$2.270M
YoY Change -102.36% -88.91% -460.32%
Pretax Income -$8.455M -$7.165M -$28.89M
YoY Change -53.85% -35.22% 404.19%
Income Tax $0.00 -$2.679M $10.00K
% Of Pretax Income
Net Earnings -$8.455M -$4.486M -$28.89M
YoY Change 218.94% 8.59% 401.82%
Net Earnings / Revenue -89.28%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.821M -$1.351M -$6.641M
COMMON SHARES
Basic Shares Outstanding 36.45M 36.45M 36.44M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.90M $76.30M $62.40M
YoY Change -46.61% -46.68% -42.22%
Cash & Equivalents $18.26M $11.02M $10.61M
Short-Term Investments $0.00 $15.10M $51.79M
Other Short-Term Assets $2.900M $1.200M $179.0K
YoY Change 13081.82% -25.0% 1093.33%
Inventory
Prepaid Expenses $615.0K
Receivables
Other Receivables
Total Short-Term Assets $73.75M $77.60M $93.25M
YoY Change -45.81% -46.37% -14.86%
LONG-TERM ASSETS
Property, Plant & Equipment $348.0K $400.0K $2.121M
YoY Change 7.08% 33.33% 560.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $10.60M
YoY Change
Other Assets $200.0K $200.0K $410.0K
YoY Change 0.0% 100.0% 310.0%
Total Long-Term Assets $593.0K $600.0K -$11.67M
YoY Change 4.04% 50.0% -2980.49%
TOTAL ASSETS
Total Short-Term Assets $73.75M $77.60M $93.25M
Total Long-Term Assets $593.0K $600.0K -$11.67M
Total Assets $74.34M $78.20M $81.59M
YoY Change -45.6% -46.11% -25.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.467M $1.200M $1.052M
YoY Change -70.07% -64.71% -64.8%
Accrued Expenses $1.097M $1.400M $5.483M
YoY Change -25.07% 16.67% 101.06%
Deferred Revenue $10.99M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.564M $2.600M $14.87M
YoY Change -63.28% -43.48% 160.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $34.00K $0.00 $15.00K
YoY Change 209.09% -21.05%
Total Long-Term Liabilities $34.00K $0.00 $15.00K
YoY Change 209.09% -21.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.564M $2.600M $14.87M
Total Long-Term Liabilities $34.00K $0.00 $15.00K
Total Liabilities $3.598M $2.600M $27.87M
YoY Change -62.97% -43.48% 385.96%
SHAREHOLDERS EQUITY
Retained Earnings -$161.2M -$69.65M
YoY Change -2.45%
Common Stock $236.8M $9.262M
YoY Change 6.22% -94.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$72.43M -$64.53M -$60.37M
YoY Change
Total Liabilities & Shareholders Equity $74.34M $78.21M $81.59M
YoY Change -45.6% -46.09% -25.79%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q4
OPERATING ACTIVITIES
Net Income -$8.455M -$4.486M -$28.89M
YoY Change 218.94% 8.59% 401.82%
Depreciation, Depletion And Amortization $40.00K $30.00K $40.00K
YoY Change 33.33% 0.0% 100.0%
Cash From Operating Activities -$5.340M -$8.352M -$25.64M
YoY Change -62.76% -30.68% 232.12%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$30.00K
YoY Change -100.0% -100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $15.00M $42.50M $36.00M
YoY Change -40.0% -222.83% -546.65%
Cash From Investing Activities $15.00M $4.445M $35.97M
YoY Change -39.95% -112.84% -544.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 42.00K -10.00K
YoY Change -100.0% -99.91%
NET CHANGE
Cash From Operating Activities -5.340M -8.352M -25.64M
Cash From Investing Activities 15.00M 4.445M 35.97M
Cash From Financing Activities 0.000 42.00K -10.00K
Net Change In Cash 9.660M -3.865M 10.32M
YoY Change -31.92% -2880.58% -165.28%
FREE CASH FLOW
Cash From Operating Activities -$5.340M -$8.352M -$25.64M
Capital Expenditures $0.00 $0.00 -$30.00K
Free Cash Flow -$5.340M -$8.352M -$25.61M
YoY Change -62.68% -30.82% 233.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36445751
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020Q1 dei Trading Symbol
TradingSymbol
TORC
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity File Number
EntityFileNumber
001-38359
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3305277
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
CY2020Q1 dei City Area Code
CityAreaCode
857
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
315-5528
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57699000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1707000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
73000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
93253000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
245000
CY2019Q4 us-gaap Assets
Assets
93912000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6716000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5483000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12199000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
15000
CY2019Q4 us-gaap Liabilities
Liabilities
12214000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
236751000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
235777000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33774000
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
12th Floor
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
500 Boylston Street
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
414000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4841000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8852000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2539000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2839000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
7380000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
11691000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-7038000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11069000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-161170000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-154132000
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
32000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
49000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
75617000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
81698000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78206000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93912000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36445751
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36444732
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11691000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7031000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36445169
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29014750
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
73000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7055000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10996000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
975000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
104204000
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
662000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
140456000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-7038000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-11069000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-71000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
247000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
34000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
27000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
975000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
663000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-542000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
81000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5506000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
144000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4128000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1482000
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
9000
CY2019Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15041000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12049000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
42500000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
42500000
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
77104000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42500000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34628000
CY2019Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
46816000
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46816000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27458000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
139000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34019000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7126000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61477000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7181000
CY2019Q1 torc Accrued Unpaid Issuance Costs Public Offering
AccruedUnpaidIssuanceCostsPublicOffering
231000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:normal;font-style:normal;"> </font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities, as of the date of the condensed consolidated financial statements, and the reported amounts of any expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to accrued liabilities, income taxes, and stock-based compensation expense. Management bases its estimates on historical experience, and on various other market-specific relevant assumptions that management believes to be reasonable, under the circumstances. Actual results may differ from those estimates or assumptions. </p>
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3056298
CY2020Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-07-05
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
15079000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
32000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
49000
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
15079000
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
15111000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
57699000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
57650000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
572000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
158000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
526000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1643000
CY2020Q1 torc Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
96000
CY2019Q4 torc Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
516000
CY2020Q1 torc Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
627000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
153000
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4162361
CY2020Q1 us-gaap Litigation Reserve
LitigationReserve
0
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1731777
CY2019 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
8
CY2020Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
2
CY2019Q4 us-gaap Litigation Reserve
LitigationReserve
0
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
100000
CY2020Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
500000
CY2020Q1 us-gaap Restructuring And Related Cost Expected Cost Remaining1
RestructuringAndRelatedCostExpectedCostRemaining1
96000
CY2019 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.22

Files In Submission

Name View Source Status
0001564590-20-022817-index-headers.html Edgar Link pending
0001564590-20-022817-index.html Edgar Link pending
0001564590-20-022817.txt Edgar Link pending
0001564590-20-022817-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
torc-10q_20200331.htm Edgar Link pending
torc-20200331.xml Edgar Link completed
torc-20200331.xsd Edgar Link pending
torc-20200331_cal.xml Edgar Link unprocessable
torc-20200331_def.xml Edgar Link unprocessable
torc-20200331_lab.xml Edgar Link unprocessable
torc-20200331_pre.xml Edgar Link unprocessable
torc-ex311_7.htm Edgar Link pending
torc-ex312_9.htm Edgar Link pending
torc-ex321_10.htm Edgar Link pending